Monday, May 04, 2026 11:54:58 PM
Here now looking forward ... new patent.
Go to Livimmune
r/Livimmune
•
11h ago
IAMLOCOTOO
New Patent Approved
From Hangout (MJS719)
docket: 230042.429
USPC new status: patented
case date of new status: 04/29/2026
The new status reflects the last status in public patent application information retrieval (pair) as of 11:59 p.m. et on the date noted above.
The patent application 17/631,161, titled "Methods for treating metastatic colon cancer with leronlimab," has officially transitioned from "pending" to "patented" as of April 29, 2026.
This change signifies that the United States Patent and Trademark Office (USPTO) has concluded its examination, found the claims to be novel and non-obvious, and granted the legal rights for the described treatment methods to CytoDyn Inc..
Key Details of the Change:
New Legal Status: Patented (formerly Pending).
Effective Date: April 29, 2026.
Scope of Protection: The patent covers specific methods of using leronlimab (a humanized CCR5-targeting monoclonal antibody) to treat patients with metastatic colorectal cancer (mCRC).Clinical Context: This grant coincides with recent clinical progress. In April 2026, CytoDyn reported early Phase 2 data showing that leronlimab, in combination with TAS-102 and bevacizumab, demonstrated biomarker activity and potential to modulate the tumor microenvironment in heavily pretreated mCRC patients.
Significance of the Grant
By moving to "patented" status, the company now holds enforceable rights to prevent others from using, selling, or importing the specific therapeutic methods claimed in the application for the duration of the patent's term. This is a critical milestone for the commercial protection of the CLOVER clinical trial regimen (leronlimab + oral chemotherapy + VEGF inhibitor).
Source: https://investorshangout.com/post/view?id=6827876
Go to Livimmune
r/Livimmune
•
11h ago
IAMLOCOTOO
New Patent Approved
From Hangout (MJS719)
docket: 230042.429
USPC new status: patented
case date of new status: 04/29/2026
The new status reflects the last status in public patent application information retrieval (pair) as of 11:59 p.m. et on the date noted above.
The patent application 17/631,161, titled "Methods for treating metastatic colon cancer with leronlimab," has officially transitioned from "pending" to "patented" as of April 29, 2026.
This change signifies that the United States Patent and Trademark Office (USPTO) has concluded its examination, found the claims to be novel and non-obvious, and granted the legal rights for the described treatment methods to CytoDyn Inc..
Key Details of the Change:
New Legal Status: Patented (formerly Pending).
Effective Date: April 29, 2026.
Scope of Protection: The patent covers specific methods of using leronlimab (a humanized CCR5-targeting monoclonal antibody) to treat patients with metastatic colorectal cancer (mCRC).Clinical Context: This grant coincides with recent clinical progress. In April 2026, CytoDyn reported early Phase 2 data showing that leronlimab, in combination with TAS-102 and bevacizumab, demonstrated biomarker activity and potential to modulate the tumor microenvironment in heavily pretreated mCRC patients.
Significance of the Grant
By moving to "patented" status, the company now holds enforceable rights to prevent others from using, selling, or importing the specific therapeutic methods claimed in the application for the duration of the patent's term. This is a critical milestone for the commercial protection of the CLOVER clinical trial regimen (leronlimab + oral chemotherapy + VEGF inhibitor).
Source: https://investorshangout.com/post/view?id=6827876
Recent CYDY News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
